Tuberculosis drug development: Progress, challenges, and the road ahead

Tuberculosis

Volumn 90, Issue 3, 2010, Pages 162-167

  Ginsberg, Ann M ^a  

^a GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

Author keywords

Biomarker; Capacity building; Drug development; Good Clinical Practice; Multi drug regimen; Tuberculosis

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BCG VACCINE; DIARYLQUINOLINE DERIVATIVE; ETHAMBUTOL; ETHYLENEDIAMINE DERIVATIVE; GAMMA1B INTERFERON; GATIFLOXACIN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; ISONIAZID; LINEZOLID; LL 3858; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; NITROIMIDAZOLE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; PNU 100480; PYRROLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAMPICIN DERIVATIVE; RIFAMYCIN DERIVATIVE; RIFAPENTINE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; CLINICAL TRIAL; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; DRUG SYNTHESIS; DRUG TOLERABILITY; EPIDEMIC; FLU LIKE SYNDROME; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RELAPSE; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; OXAZOLIDINONES; RIFAMYCINS; TUBERCULOSIS;

EID: 77952545901     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2010.03.003     Document Type: Review

References (45)

1. Rosenthal I.M., Zhang M., Williams K.N., Peloquin C.A., Tyagi S., Vernon A.A., et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 4 (2007) e344
2. St. George's Hospital Medical School, An international multicentre controlled clinical trial to evaluate high dose RIFApentine and a QUINolone in the treatment of pulmonary tuberculosis high dose RIFApentine high dose RIFApentine and a QUINolone in the treatment of pulmonary tuberculosis (RIFAQUIN), ISRCTN44153044, http://apps.who.int/trialsearch/default.aspx.
3. APRIORI, Pharmacokinetics and pharmacodynamics of high versus standard dose rifampicin in patients with pulmonary tuberculosis (High RIF), clinicaltrials.gov identifier NCT00760149.
4. Johns Hopkins University, Study of daily rifapentine for pulmonary tuberculosis, clinicaltrials.gov identifier NCT00814671.
5. U.S. Centers for Disease Control and Prevention, TBTC Study 29: rifapentine during intensive phase tuberculosis (TB) treatment, clinicaltrials.gov identifier NCT00694629.
6. Martinez E., Collazos J., and Mayo J. Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Medicine (Baltimore) 78 (1999) 361-369
7. Dooley K., Flexner C., Hackman J., Peloquin C.A., Nuermberger E., Chaisson R.E., et al. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother 52 (2008) 4037-4042
8. Gatifloxacin: clinicaltrials.gov identifier: NCT00216385.
9. Moxifloxacin: clinicaltrials.gov idenitifier: NCT00864383.
10. Vinh D.C., and Rubinstein E. Linezolid: a review of safety and tolerability. J Infect 59 Suppl. 1 (2009) S59-S74
11. Schecter G.F., Scott C., True L., Raftery A., Flood J., and Mase S. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 50 (2010) 49-55
12. Migliori G.B., Eker B., Richardson M.D., Sotgiu G., Zellweger J.P., Skrahina A., et al., TBNET Study Group. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 34 (2009) 387-393
13. Dietze R., Hadad D.J., McGee B., Molino L.P., Maciel E.L., Peloquin C.A., et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 178 11 (2008 Dec 1) 1180-1185
14. U.S. National Institutes of Health, A phase 2a, randomized, 2-Arm, open-label, clinical trial of the efficacy of linezolid combined with antituberculous therapy in subjects with Extensively Drug-Resistant (XDR) pulmonary tuberculosis, http://clinicaltrials.gov/ct2/show/NCT00727844.
15. TBTC Study 30: A Phase I/II Pilot Study for Evaluation of Low Dose, Once Daily, Linezolid Plus Optimized Background Therapy (OBT) Versus Placebo Plus OBT for the Treatment of Multi-Drug Resistant Tuberculosis. clinicaltrials.gov/ct2/show/NCT00664313.
16. Williams K.N., Brickner S.J., Stover C.K., Zhu T., Ogden A., Tasneen R., et al. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am J Respir Crit Care Med 180 4 (2009 Aug 15) 371-376
17. Clinicaltrials.gov identifier: NCT00871949.
18. Singh R., Manjunatha U., Boshoff H.I., Ha Y.H., Niyomrattanakit P., Ledwidge R., et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322 (2008) 1392-1395
19. Clinicaltrials.gov identifier: NCT00685360.
20. Ginsberg A.M., Laurenzi M.W., Rouse D.J., Whitney K.D., and Spigelman M.K. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob Agents Chemother 53 (2009) 3720-3725 Epub 2009 Jun 15
21. Ginsberg A.M., Laurenzi M.W., Rouse D.J., Whitney K.D., and Spigelman M.K. Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects. Antimicrob Agents Chemother 53 9 (2009 Sep) 3726-3733 Epub 2009 Jun 15
22. Diacon AH, Dawson R, Hanekom M, Narunsky K, Maritz SJ, Venter A, et al. The safety, tolerability and early bactericidal activity and pharmacokinetics of PA824 in previously untreated, uncomplicated, sputum smear-positive pulmonary tuberculosis patients, Antimicrob Agents Chemother, in press.
23. Diacon A.H., Pym A., Grobusch M., Patientia R., Rustomjee R., Page-Shipp L., et al. The diarylquinoline TMC207 for multidrug resistant tuberculsosis. N Engl J Med 360 (2009) 2397-2405
24. Boshoff H.I., Myers T.G., Copp B.R., McNeil M.R., Wilson M.A., and Barry III C.E. The transcriptional responses of M. tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem 279 (2004) 40174-40184
25. Horwith G, Einck L, Protopopova M, Nacy C. Abstract of presentation, In: 45th IDSA annual meeting, San Diego, CA; Oct 4-7, 2007.
26. Clinicaltrials.gov identifier: NCT00866190.
27. Personal communication: Dr. Rajender Kamboj, President, Novel Drug Discovery & Development, Lupin Limited, Pune, India to Stop TB Partnership Working Group on New Drugs, 30 September 2008.
28. Hawkridge A., Hatherill M., Little F., Goetz M.A., Barker L., Mahomed H., et al. South African BCG trial team. Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial. BMJ 337 (2008) a2052
29. van Niekerk C., and Ginsberg A. Assessment of global capacity to conduct tuberculosis drug development trials: do we have what it takes?. Int J Tuberc Lung Dis 13 (2009) 1367-1372
30. Fox W., Willard G.A., and Mitchison D.A. Studies on the treatment of tuberculosis undertaken by the British medical research council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 3 (1999) S231-S279
31. Recently reviewed in REF:. Churchyard G.J., Kaplan G., Fallows D., Wallis R.S., Onyebujoh P., and Rook G.A. Advances in immunotherapy for tuberculosis treatment. Clin Chest Med 30 4 (2009 Dec) 769-782
32. Dawson R., Condos R., Tse D., Huie M.L., Ress S., Tseng C., et al. Immunomodulation with recombinant interferon-γ1b in pulmonary tuberculosis. PLoS One 4 9 (2009) e6984
33. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. BMJ 2 (1948) 769-782
34. Medical Research Council. The prevention of streptomycin resistance by combined chemotherapy. BMJ 1 (1952) 1157-1162
35. Mitchison D.A. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 147 (1993) 1062-1063
36. Ruslami R., Nijland H.M., Alisjahbana B., Parwati I., van Crevel R., and Aarnoutse R.E. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother 51 7 (2007 Jul) 2546-2551 Epub 2007 Apr 23
37. Jayaram R., Gaonkar S., Kaur P., Suresh B.L., Mahesh B.N., Jayashree R., et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 47 (2003) 2118-2124
38. Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 360 (2002) 528-534
39. Vernon A., Burman W., Benator D., Khan A., and Bozeman L. Acquired rifamycin mono-resistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 353 (1999) 1843-1847
40. Chapuis L., Ji B., Truffot-Pernot C., O'Brien R.J., Raviglione M.C., and Grosset J.H. Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am J Respir Crit Care Med 150 (1994) 1355-1362
41. Yadav V., and Deopujari K. Gatifloxacin and dysglycemia in older adults. N Engl J Med 354 25 (2006 Jun 22) 2725-2726 author reply 2725-26
42. Park-Wyllie L.Y., Juurlink D.N., Kopp A., Shah B.R., Stukel T.A., Stumpo C., et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 354 (2006) 1352-1361
43. Nikonenko B.V., Protopopova M., Samala R., Einck L., and Nacy C.A. R63; Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob Agents Chemother 51 4 (2007 Apr) 1563-1565 Epub 2007 Jan 22
44. Protopopova M., Hanrahan C., Nikonenko B., Samala R., Chen P., Gearhart J., Einck L., and Nacy C.A. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1, 2-ethylenediamines. J Antimicrob Chemother 56 5 (2005 Nov) 968-974 Epub 2005 Sep 19.
45. Deidda D., Lampis G., Fioravanti R., Biava M., Poretta G.C., Zanetti S., et al. Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic M. tuberculosis strains. Antimicrob Agents Chemother 42 (1998) 3035-3037